537,188 Insmed, Inc. $INSM Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lifted its position in shares of Insmed, Inc. (NASDAQ:INSM) by 44.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,757,541 shares of the biopharmaceutical company’s stock after acquiring an additional 537,188 shares during the period. Pictet Asset Management Holding SA’s holdings in Insmed were worth $200,845,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Sei Investments Co. increased its holdings in shares of Insmed by 56.8% in the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock worth $228,239,000 after acquiring an additional 505,624 shares during the period. NWI Management LP lifted its position in Insmed by 2.6% in the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock valued at $165,809,000 after purchasing an additional 25,540 shares during the last quarter. Principal Financial Group Inc. lifted its position in Insmed by 18.8% in the 1st quarter. Principal Financial Group Inc. now owns 916,464 shares of the biopharmaceutical company’s stock valued at $149,860,000 after purchasing an additional 145,106 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Insmed by 480.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock valued at $144,591,000 after purchasing an additional 1,048,518 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Insmed during the 2nd quarter valued at about $139,966,000.

Insmed Price Performance

Shares of INSM opened at $114.40 on Monday. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The stock’s fifty day moving average is $111.21 and its 200-day moving average is $124.36. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86. The firm has a market capitalization of $25.10 billion, a price-to-earnings ratio of -40.57 and a beta of 0.83.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The company had revenue of $524.43 million during the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The business’s revenue for the quarter was up 268.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.75) EPS. Equities analysts anticipate that Insmed, Inc. will post -1.86 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on INSM shares. Raymond James Financial set a $173.00 target price on shares of Insmed in a research report on Tuesday, October 20th. Guggenheim cut their price target on Insmed from $205.00 to $201.00 and set a “buy” rating on the stock in a report on Monday, November 2nd. UBS Group reaffirmed a “buy” rating on shares of Insmed in a report on Thursday, October 8th. Wolfe Research downgraded Insmed from an “outperform” rating to a “peer perform” rating in a research report on Monday, October 12th. Finally, Morgan Stanley decreased their price objective on Insmed from $218.00 to $213.00 and set an “overweight” rating for the company in a report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus target price of $196.52.

Insider Transactions at Insmed

In other news, Director David Brennan sold 25,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the sale, the director owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. The trade was a 38.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.10% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr.

Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.